The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rituximab May Help Pediatric Patients with SLE

Rituximab May Help Pediatric Patients with SLE

July 17, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Rituximab binds to the CD20 antigen and mediates B cell depletion, actions that led to its indication for the treatment of non-Hodgkin’s lymphoma, lymphocytic leukemia, rheumatoid arthritis and granulomatosis with polyangiitis (GPA). However, clinical trials in adults have not supported its use as a treatment for systemic lupus erythematosus (SLE). A new systematic review, published online June 8 in the Journal of Pediatrics, concludes that rituximab may be a safe and effective treatment for pediatric SLE (pSLE).1

You Might Also Like
  • Rituximab Use Increasing in Treatment of Pediatric Vasculitis
  • Multimodal Imaging May Uncover Neural Mechanisms in Pediatric Neuropsychiatric Lupus
  • Intronic Polymorphism Associated with Risk of Neurological Disorders in SLE
Also By This Author
  • TNF Stabilizes Inflammatory RNA in Synoviocytes

Ines Mahmoud, PhD, a researcher at Mar University in Tunisia, and colleagues conducted a systematic search of clinical trials and observational studies that yielded 549 citations. Twelve case series (three multicenter and three prospective) met the authors’ criteria for data extraction according to an 18-criteria checklist using a modified Delphi method. None of the studies included a control group. In total, the case series included 272 patients with active disease who were refractory to steroids and immunosuppressant drugs. The studies were predominantly British, American and Canadian (60% of patients), and refractory lupus nephritis was the most common indication (33%) for rituximab therapy. However, children were also treated for other disease manifestations, including cytopenia, vasculitis, arthritis, serositis, neuropsychiatric disease, skin disorders, pulmonary hypertension, ophthalmic disorders and general symptoms.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The studies point to a conclusion that rituximab is safe and effective as a treatment for renal and hematologic manifestations of pSLE. Treated patients experienced significant improvement in renal function and reduction in proteinuria within two to 12 months. Additionally, the children who received rituximab as a treatment for refractory autoimmune cytopenia achieved complete remission. Three studies also reported statistically significant, short-term (one to eight months) improvements in disease activity.

In their review, the authors note that one of the main goals in the treatment of SLE is the prevention of relapse. When they looked through the literature for that particular outcome, they found that only three studies reported relapses and from these studies they calculated a relapse rate that ranged from 9–30% following treatment with rituximab, with a median time to relapse of two to 22 months.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The authors found that rituximab seemed to have a steroid-sparing effect in pediatric patients. Patients also showed improvements in neuropsychiatric manifestations, disease activity, complement and anti-double stranded Deoxy-Nucelo-Adenosine. In particular, C3 values increased in eight studies and C4 values increased in six studies. The two studies that evaluated neuropsychiatric manifestations both reported significant clinical improvement for this endpoint. In contrast, however, there was poor evidence to suggest efficacy for arthralgia, photosensitivity and mucocutaneous manifestations of SLE in children.

Pages: 1 2 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: Pediatric, rituximab, SLE, systemic lupus erythematosus (SLE)

You Might Also Like:
  • Rituximab Use Increasing in Treatment of Pediatric Vasculitis
  • Multimodal Imaging May Uncover Neural Mechanisms in Pediatric Neuropsychiatric Lupus
  • Intronic Polymorphism Associated with Risk of Neurological Disorders in SLE
  • Physical & Cognitive Function in SLE Patients

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)